120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于去脂体重的病态肥胖患者全身麻醉诱导期间环泊酚ED50和ED95测定：一项单中心上下序贯研究
Authors Wu CM , Wu JM, Jiang JX, Xu QM , Han XH, Duan GC
Received 18 September 2025
Accepted for publication 19 January 2026
Published 24 January 2026 Volume 2026:20 568472
DOI https://doi.org/10.2147/DDDT.S568472
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Muzammal Hussain
Chao-min Wu, Ji-min Wu, Jian-xin Jiang, Qiao min Xu, Xue-hao Han, Gong-chen Duan
Department of Anesthesiology, Lishui People’s Hospital, The First Affiliated Hospital of Lishui University, Wenzhou Medical University Lishui Hospital, Lishui, People’s Republic of China
Correspondence: Gong-chen Duan, Department of Anesthesiology, Lishui People’s Hospital, The First Affiliated Hospital of Lishui University, Wenzhou Medical University Lishui Hospital, No. 1188, Liyang Street, Lishui, Zhejiang, 323000, People’s Republic of China, Tel/Fax +8618957093030, Email 981225178@qq.com
Background: Obesity alters the pharmacokinetics and pharmacodynamics of hypnotic agents; however, dose-finding data for ciprofol during the induction of general anesthesia in morbidly obese adults remain limited. We estimated the lean body weight (LBW)-scaled 50% effective dose (ED50) and 95% effective dose (ED95) of ciprofol for loss of consciousness by using an up and down sequential design.
Methods: This prospective single-center trial enrolled adults aged 18– 65 years with morbid obesity who underwent elective surgery. Ciprofol was administered as a slow intravenous bolus at an initial dose of 0.76 mg kg− 1 (LBW), followed by an up and down algorithm with an adjacent dose ratio of 1.1. Primary outcome: LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness. ED50 and ED95 values were estimated using probit analysis. Hemodynamics and adverse events were collected as pre-specified secondary endpoints.
Results: Thirty-six patients were included in the study. The sequence yielded either successful or failed crossovers. The LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness were 0.492 mg kg− 1 (95% CI 0.453– 0.531) and 0.634 mg kg− 1 (95% CI 0.524– 0.744), respectively. The mean arterial pressure and heart rate decreased after induction, reaching a nadir approximately 5 min after tracheal intubation, and generally remained ≥ 70% of baseline for most patients. In exploratory, post hoc comparisons of response-defined groups, the incidence of hypotension (37% vs 41%, p=0.79), bradycardia (5% vs 6%, p=0.94), and tachycardia (26% vs 35%, p=0.27) was similar. No other adverse events were reported.
Conclusion: The LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness during the induction of general anesthesia in morbidly obese adults were 0.492 and 0.634 mg kg− 1, respectively. Hemodynamics were generally well controlled and adverse events were infrequent.
Keywords: ciprofol, morbidly obese, anesthesia induction, 50% effective dose, 95% effective dose
Department of Anesthesiology, Lishui People’s Hospital, The First Affiliated Hospital of Lishui University, Wenzhou Medical University Lishui Hospital, Lishui, People’s Republic of China
Correspondence: Gong-chen Duan, Department of Anesthesiology, Lishui People’s Hospital, The First Affiliated Hospital of Lishui University, Wenzhou Medical University Lishui Hospital, No. 1188, Liyang Street, Lishui, Zhejiang, 323000, People’s Republic of China, Tel/Fax +8618957093030, Email 981225178@qq.com
Background: Obesity alters the pharmacokinetics and pharmacodynamics of hypnotic agents; however, dose-finding data for ciprofol during the induction of general anesthesia in morbidly obese adults remain limited. We estimated the lean body weight (LBW)-scaled 50% effective dose (ED50) and 95% effective dose (ED95) of ciprofol for loss of consciousness by using an up and down sequential design.
Methods: This prospective single-center trial enrolled adults aged 18– 65 years with morbid obesity who underwent elective surgery. Ciprofol was administered as a slow intravenous bolus at an initial dose of 0.76 mg kg− 1 (LBW), followed by an up and down algorithm with an adjacent dose ratio of 1.1. Primary outcome: LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness. ED50 and ED95 values were estimated using probit analysis. Hemodynamics and adverse events were collected as pre-specified secondary endpoints.
Results: Thirty-six patients were included in the study. The sequence yielded either successful or failed crossovers. The LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness were 0.492 mg kg− 1 (95% CI 0.453– 0.531) and 0.634 mg kg− 1 (95% CI 0.524– 0.744), respectively. The mean arterial pressure and heart rate decreased after induction, reaching a nadir approximately 5 min after tracheal intubation, and generally remained ≥ 70% of baseline for most patients. In exploratory, post hoc comparisons of response-defined groups, the incidence of hypotension (37% vs 41%, p=0.79), bradycardia (5% vs 6%, p=0.94), and tachycardia (26% vs 35%, p=0.27) was similar. No other adverse events were reported.
Conclusion: The LBW-scaled ED50 and ED95 of ciprofol for loss of consciousness during the induction of general anesthesia in morbidly obese adults were 0.492 and 0.634 mg kg− 1, respectively. Hemodynamics were generally well controlled and adverse events were infrequent.
Keywords: ciprofol, morbidly obese, anesthesia induction, 50% effective dose, 95% effective dose